Monopar Therapeutics Inc Statistics
Monopar Therapeutics Inc (1IY0) Stock Statistics & Valuation Metrics
Total Valuation
Monopar Therapeutics Inc has a market cap or net worth of EUR 431.38M. The enterprise value is EUR 656.75M.
- Market Cap
- EUR 431.38M
- Enterprise Value
- EUR 656.75M
Share Statistics
Monopar Therapeutics Inc has 6,712,172 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,712,172
- Owned by Insiders
- 13.88%
- Owned by Institutions
- 17.00%
Financial Efficiency
Monopar Therapeutics Inc’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -12.11%.
- Return on Equity (ROE)
- -0.10
- Return on Assets (ROA)
- -0.10
- Return on Invested Capital (ROIC)
- -12.11%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 0
- Profits Per Employee
- -623.50K
- Employee Count
- 22
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Monopar Therapeutics Inc is -30.68. Monopar Therapeutics Inc’s PEG ratio is 1.07.
- PE Ratio
- -30.68
- PS Ratio
- 0.00
- PB Ratio
- 4.69
- Price to FCF
- -0.15
- Price to Operating Cash Flow
- -0.19
- PEG Ratio
- 1.07
Income Statement
In the last 12 months, Monopar Therapeutics Inc had revenue of 0 and earned -13.72M in profits. Earnings per share was -1.85.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -16.70M
- Pretax Income
- -13.72M
- Net Income
- -13.72M
- EBITDA
- -13.72M
- Earnings Per Share (EPS)
- -1.85
Cash Flow
In the last 12 months, operating cash flow was -3.26B and capital expenditures -4, giving a free cash flow of -3.26B billion.
- Operating Cash Flow
- -3.26B
- Free Cash Flow
- -3.26B
- Free Cash Flow per Share
- -381.20
Dividends & Yields
Monopar Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -675.92%
- Earnings Yield
- -2.91%
Stock Price Statistics
- Beta
- 9.72
- 52-Week Price Change
- -4.78%
- 50-Day Moving Average
- 75.36
- 200-Day Moving Average
- 65.07
- Relative Strength Index (RSI)
- 37.19
- Average Volume (3m)
- ―
Important Dates
Monopar Therapeutics Inc upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Monopar Therapeutics Inc as a current ratio of 51.35, with Debt / Equity ratio of 0.11%
- Current Ratio
- 51.35
- Quick Ratio
- 51.35
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 4.50
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Monopar Therapeutics Inc has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Monopar Therapeutics Inc EV to EBITDA ratio is -23.20, with an EV/FCF ratio of -0.13.
- EV to Sales
- 0.00
- EV to EBITDA
- -23.20
- EV to Free Cash Flow
- -0.13
- EV to Operating Cash Flow
- -0.13
Balance Sheet
Monopar Therapeutics Inc has EUR 134.30M in cash and marketable securities with EUR 107.83K in debt, giving a net cash position of EUR 134.19M billion.
- Cash & Marketable Securities
- EUR 134.30M
- Total Debt
- EUR 107.83K
- Net Cash
- EUR 134.19M
- Net Cash Per Share
- EUR 19.99
- Tangible Book Value Per Share
- EUR 15.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Monopar Therapeutics Inc is EUR 115.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 115.20
- Price Target Upside
- 80.56% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 35.19%
Scores
- Smart Score
- 3
- AI Score
- ―
